Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study

ACTRN 12622000016730

Brief Summary

Patients with previously untreated HER2-positive locally advancedat a late stage, far along or metastatic breast cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs who are suitable for treatment with the combination of prochlorperazine and standard systemic therapy with paclitaxel, pertuzumab, and trastuzumab systemic therapy.

Intervention/Treatment

• Drug: Prochlorperazine (PCZ)
• Drug: Paclitaxel
• Drug: Trastuzumab
• Drug: Pertuzumab

Inclusion Criteria

1. Patients with previously untreated HER2-positive locally advanced or metastatic breast cancer who are suitable for treatment with the combination of prochlorperazine and standard systemic therapy with paclitaxel, pertuzumab, and trastuzumab systemic therapy.